Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Many GPs incorrectly view nicotine as more harmful than smoke, despite understanding that smoking is riskier. This misunderstanding may influence advice on alternative nicotine products.
A new study found that only one-fifth of rheumatoid arthritis patients took their oral medications at 80% or greater. Researchers emphasize the importance of following the prescribed regimen to manage disease symptoms and prevent progression. Patients with better mental health status were more likely to adhere to their medication regimen.
Researchers at Fox Chase Cancer Center are conducting further tests on the drug nivolumab, a monoclonal antibody that targets the immune system's response to cancer. The therapy appears to produce largely manageable side effects and has shown potential in treating tumors more effectively than current treatments.
Scientists have designed nanoparticles that can flip from a sphere to a net-like structure in response to tumor signals, accumulating at the site of cancer. This new approach aims to target treatments specifically to diseased cells, overcoming current limitations.
A national survey found that adults often did not make informed medical decisions due to insufficient shared decision-making. Healthcare providers need to improve patient engagement by balancing discussions on pros and cons and regularly seeking patient input.
A recent study suggests that movie advertisements for alcohol products can influence adolescent drinking behavior and that current regulations are insufficient to restrict these placements. The authors propose rating system changes to restrict depictions of drinking in youth-rated movies.
Despite promising initial results, a breakthrough treatment for Alzheimer's disease did not show any reduction in plaque burden after extensive testing. Three independent research groups failed to confirm the efficacy of bexarotene in reversing beta amyloid plaques.
A recent study published in Cell Reports reveals how certain genes control the ratio of proteins p21 and PUMA, which determines whether tumors adapt or die when faced with p53-activating drugs. The researchers found a handful of genes that fine-tune this balance.
Researchers have developed a new drug delivery system that uses nanoparticles and siRNA to target lung cancer cells, eliminating resistance and reducing systemic damage. In laboratory tests, the system showed significant improvement in treating lung tumors, with nearly 83% of the drug delivered directly to the lungs.
Researchers successfully targeted doxorubicin to mitochondria, killing cancer cells even those with developed pumps. The study suggests this approach could work with other nucleus-targeting anti-cancer drugs.
A study published in JAMA Internal Medicine found that intensity-modulated radiotherapy (IMRT) and conformal radiotherapy (CRT) had similar morbidity and cancer control outcomes after prostatectomy. The use of IMRT did not result in significant differences in long-term gastrointestinal or urinary symptoms.
A University of Michigan Health System study found that peripherally inserted central catheters more than double the risk of blood clots in critically ill patients and those with cancer. The device is often used for IV medication delivery and has lower infection risks, but may not be suitable for all patients.
Researchers have identified Dkk1 as a key player in the development of atherosclerosis, a condition that causes arteries to become stiff and narrow, leading to impaired blood flow. Targeting Dkk1 signaling may help limit arteriosclerotic disease, according to a new study.
Scientists at Texas Biomedical Research Institute have identified four genes (TENC1, ERBB3, ACVR1B, and DGKA) that influence levels of low-density lipoprotein (LDL) cholesterol. This discovery could lead to the development of new drugs to reduce heart disease risk in humans.
A first prospective trial, CUSTOM, demonstrates that genetic analysis can assign cancer treatment for patients with three types of cancers. The study found that patients and doctors are interested in personalized medicine, but rare mutations remain a challenge.
A novel agent, (S)-YK-4-279, has been shown to halt the progression of Ewing sarcoma in rats and cause tumor regression. The agent works by blocking protein-protein interaction between cancer-causing proteins.
A new study by Penn Medicine found that most cancer doctors, patients, and the general public support cutting healthcare costs by refusing to pay for drugs without improving survival or quality of life. The survey also revealed that large numbers favored not paying for more expensive drugs when cheaper alternatives are equally effective.
A new drug has shown significant promise in extending survival when used in combination with radiation therapy for brain cancer patients. The experimental drug, KU-60019, blocks the activation of ATM kinase, leading to enhanced destruction of glioma cells.
Researchers found that a tumor-activated protein, VEGF-C, activates integrin α4β1 on lymphatic vessels in lymph node tissues, making them more attractive to metastatic tumor cells. This highlights the way tumors can have long-range effects on other parts of the body, impacting tumor metastasis or growth.
The article reports on a major examination of the status of new drugs for rare diseases, which affect 200,000 patients or fewer. Pharmaceutical companies are investing in research and marketing new medicines, driven by factors such as patient advocacy groups, venture capital firms, and government incentives.
Researchers used low doses of leukemia drug nilotinib to clear toxic proteins from mouse brains affected with Parkinson's disease and other neurodegenerative disorders. The treatment improved movement and functionality in treated mice compared to untreated ones, offering a promising therapeutic strategy for these diseases.
Researchers at Oregon Health & Science University have isolated a molecular mutation causing two rare forms of leukemia. The study suggests that patients with these conditions could be helped by existing FDA-approved drugs, paving the way for potential treatment breakthroughs.
A new study found that metformin, a commonly used diabetes drug, did not improve survival rates in older breast cancer patients with diabetes. The study, published in Diabetes Care, examined 2,361 women aged 66 or older and followed them until death or March 30, 2010.
Researchers identified immune gene signatures that predict cancer recurrence in certain breast cancer types, such as basal-like or triple negative disease. These signatures can help doctors make informed treatment decisions and may lead to valuable new strategies in personalized medicine.
Researchers at Lund University are testing an antibody-based treatment for multiple myeloma, a type of blood cancer without a cure. The antibody, BI-505, has shown promising results in cell studies and animal experiments, and a clinical trial is currently underway to test its effects on patients.
A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time. The drug, Dz13, was found to be safe and showed positive effects in reducing tumour growth and spread.
A novel high-throughput screening method has identified agents that can block EZH2 methyltransferase, a key enzyme in tumor development. This approach uses AlphaLisa technology to detect methylation and accelerates the identification of small molecule inhibitors for cancer treatment.
A study found a statistically non-significant but clinically significant benefit in adding everolimus to trastuzumab treatment for HER-2 positive early breast cancer. The combination improved clinical response rates, but not pathological response rates, suggesting benefits independent of expected molecular pathways.
A recent study has revealed the magnitude of variation in gene expression measurements within breast cancers. Combining samples from multiple biopsies from a single tumour can effectively overcome this variation for selected genes, allowing for more precise treatment tailoring and reliable predictions related to disease progression.
Researchers at Case Western Reserve University School of Medicine have identified a novel method to disrupt a common cancer pathway, suggesting a new treatment for breast, colon, melanoma and other cancers. The breakthrough was achieved by targeting a mutation in the PIK3CA gene.
Researchers found that men with prostate cancer who take statin drugs are significantly less likely to die from their cancer. The study, led by Janet L. Stanford, Ph.D., followed over 1,000 Seattle-area prostate cancer patients for almost eight years and found a 5% mortality rate among statin users versus 1% for nonusers.
Researchers at Mayo Clinic discover a protein that is overly active in every human sample of kidney cancer and find an experimental drug designed to block its activity significantly reduces tumor growth. Combining it with another drug improves effectiveness.
A comprehensive analysis of 83,399 women found SERMs significantly reduce ER-positive breast cancer incidence by 38%. The study also showed increased thromboembolic events with all SERMs except tamoxifen.
Scientists have discovered a mechanism to reactivate the tumor suppressor p53 in metastatic melanoma cells, which were previously silenced by proteins iASPP and MDM2. Treatment with a combination of small molecules JNJ-7706621 and Nutlin-3 restored p53 function and suppressed tumor growth in mice.
The increasing cost of leukemia treatments in the US is leaving many patients under- or untreated due to unaffordable care. CML experts call for a long-term solution to manage treatment costs, balancing investments from various parties.
The region faces an alarming increase in cancer rates, with more than 1.7 million cases predicted to be diagnosed by 2030 and over 1 million deaths annually. Inadequate healthcare systems, lack of access to medical care, and inadequate health insurance exacerbate the issue.
Researchers have found that the menin protein suppresses signaling in the Hedgehog pathway in endocrine organs, leading to increased cell proliferation. Inhibiting this pathway using drugs reduces tumor growth in an animal model of human MEN1 syndrome.
A study at Lund University found that drinking two or more cups of coffee daily may reduce the risk of breast cancer recurrence in patients taking Tamoxifen. Caffeine has been shown to hamper cancer cell growth and activate Tamoxifen, making it more efficient.
A study published in PLOS Medicine found that white people with a history of non-melanoma skin cancer, such as basal cell and squamous cell carcinoma, are at increased risk of developing other forms of cancer in the future. The analysis revealed a 15% to 26% higher risk for men and women, respectively.
Researchers at Moffitt Cancer Center found that a p53 deficiency can slow or delay DNA repair after radiation treatment. The study revealed that p53 regulates the expression of two enzymes, JMJD2b and SUV39H1, which control DNA folding.
A new pathway has been identified that enhances tamoxifen's effectiveness in treating basal-like breast cancer, a subtype resistant to treatment. The discovery involves targeting Cdc42 protein to restore normal function of c-Cbl and improve cancer cell death.
Researchers have discovered a new approach to weight loss by blocking blood vessels in fat tissue, leading to a significant reduction in fat mass. The study found that mice who received the cancer drug Sunitinib lost an average of 70% of their fat mass, with no impact on lean body mass.
Researchers at Karolinska Institutet developed a method to assess tamoxifen's effect on breast cancer, using mammograms. Women showing a 20% reduction in breast density have a 50% reduced risk of dying from breast cancer over 15 years.
Researchers at Ohio State University Comprehensive Cancer Center found that AS1411 reduces cancer aggressiveness by inhibiting microRNA maturation, while restoring sensitivity to fulvestrant in resistant cells. The study suggests a new strategy for treating breast cancer.
A retrospective study suggests that patients with lung cancer carrying specific HER2 mutations may experience tumor shrinkage and delayed disease progression when treated with anti-HER2 drugs. The study found 1.7% of NSCLC patients in Europe had these rare mutations, which can lead to continuous activation of the HER2 protein.
Researchers at UCLA have developed a potentially more effective treatment for triple-negative breast cancer (TNBC) using nanoscale, diamond-like particles called nanodiamonds. The new compound has been shown to decrease tumor growth and eliminate side effects of cancer treatment in mice.
Researchers identified an eight-gene signature that correlates with chemotherapy outcome in lung and breast cancer patients. The gene signature, which includes the receptor for growth factor EGF, helps predict relapse-free survival after chemotherapy.
A team of scientists at Temple University School of Medicine has identified a key molecule, GRK2, in mitochondria that contributes to the death of heart cells. The researchers found that blocking this enzyme's activity can prevent its delivery to mitochondria and reduce pro-death signaling.
James Allison's discovery of the drug ipilimumab, which blocks CTLA-4 and treats T cells not cancer, has led to a significant increase in survival rates for patients with late-stage metastatic melanoma. The AACR-CRI award recognizes his contributions to cancer immunology and builds on Dr. Lloyd Old's pioneering work in harnessing the i...
Breast cancers with high androgen receptor (AR) levels are more likely to relapse after estrogen-targeting therapies. Anti-androgen therapy shows promising responses in cell lines and preclinical models, offering a new potential target for breast cancer treatment.
The study found that while the program was rarely used, those who participated reported gratitude for receiving a lethal prescription, regardless of use. The most common reasons for participation included loss of autonomy, inability to engage in enjoyable activities, and loss of dignity. SCCA's approach prioritizes palliative care and ...
A new class of tumor-fighting drugs using RNA interference has shown promising safety and efficacy in a clinical trial. The study found that the drug acts by silencing the PLK1 gene involved in tumor growth and can be safely administered in humans, with most patients tolerating it well and some showing therapeutic benefit.
A genetic biomarker, MYCN amplification, has been identified as a potential target for a new class of anti-cancer drugs in neuroblastoma patients. The study found that tumors with excess copies of the gene were highly sensitive to BET bromodomain inhibitors, leading to impaired cell growth and induction of cell death.
Researchers found that the drug combination resulted in a 70% decrease in tumor volume compared to single-drug treatment. The study suggests that MK-1775 and gemcitabine may represent a novel approach in treating sarcomas, offering new hope for rare cancer patients.
A new study found that one-quarter of women who need hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course. Side effects were cited as the most common reason for skipping treatment.
Researchers found that Mer receptor overexpression correlates with melanoma progression and aggressiveness, driving disease severity. Investigational drug UNC1062 blocks Mer survival signaling, killing melanoma cells in dishes and mouse models.
Researchers at Penn Medicine discovered that cells with low helicase-like transcription factor (HLTF) expression are more likely to respond to autophagy inhibition. This finding could lead to the development of a predictive biomarker for patients who may benefit from this treatment approach.
The novel inhibitor XL-184 (Cabozantinib) showed significant tumor growth decrease in 12 colorectal cancer explants, with 8 exhibiting stable disease. The drug targets both VEGFR2 signaling pathway and c-MET for survival of tumor cells.
A subset of breast cancer patients with HER-2 positive tumors may benefit from a combination of targeted treatments that avoid chemotherapy. The study, published in the Journal of Clinical Oncology, shows high efficacy in eradicating tumors and offers a groundbreaking approach to treatment without significant side effects.
A new study found that long-term use of arrhythmia medication amiodarone may significantly increase the risk of developing certain cancers. Men and individuals taking high cumulative daily doses were more likely to develop cancer, with a 46% increased risk compared to those taking low doses.